Overview
EQRx was a Cambridge, Massachusetts drug developer founded to offer new medicines at prices lower than competing branded treatments. It planned to develop or license drugs for established targets, then work with insurers and health systems to make those medicines accessible if regulators approved them. [1]
The model depended on getting medicines through trials and onto the market. After regulatory discussions and changes to its development plans, EQRx conducted a strategic review. Revolution Medicines completed its acquisition in November 2023 and said it would wind down EQRx's programs. EQRx had not demonstrated its proposed pricing model through a commercial launch. [2] [3]
Founding Story
EQRx launched in January 2020 with Alexis Borisy as chairman and chief executive and Melanie Nallicheri as president and chief operating officer. Its co-founders also included oncologist Sandra Horning and physician Peter Bach. Borisy had helped launch Foundation Medicine and Blueprint Medicines; Horning had been Genentech's chief medical officer, and Bach studied drug pricing and health policy. [4] [5]
The founders argued that advances in drug development could allow a different commercial model. EQRx would pursue medicines aimed at established clinical targets and offer them at lower prices if approved. It was a proposal, not an established shortcut: the company still needed to demonstrate safety and efficacy, gain regulatory approval, and convince healthcare buyers and clinicians to adopt its drugs. [6]
Borisy told BioPharma Dive that the intended price would be “fundamentally lower,” rather than relying on a rebate. That distinction mattered because EQRx wanted to alter the price offered to payers, not merely negotiate a conventional discount after launch. The reviewed sources do not establish how the four founders first met. [6]
Timeline
- 2020: EQRx launched with a $200 million Series A, co-led by GV, ARCH, and Andreessen Horowitz. [7]
- 2021: The company announced $500 million in additional funding and later went public through a merger with a special-purpose acquisition company. [8] [2]
- 2022: EQRx reassessed its U.S. development plans after discussions about evidence needed for its lead cancer programs. [2]
- 2023: The company reduced its organization, reprioritized its portfolio, and pursued strategic options. Revolution Medicines completed the acquisition in November. [9] [3]
What They Built
EQRx planned a portfolio of medicines rather than a single drug. Its securities filing described licensing clinical and preclinical programs, working with drug-engineering partners, and developing combinations. It initially focused on oncology and immune-inflammatory disease. The company intended to offer its portfolio to payers and health systems through a group it called the Global Buyers Club. [1]
The distinction from a generic drug was material. EQRx pursued new, patent-protected medicines, including candidates intended to compete in established treatment categories. It still had to obtain approval on evidence specific to each product. A lower intended price did not substitute for clinical evidence. [5] [1]
Two late-stage candidates were aumolertinib, an EGFR inhibitor, and sugemalimab, an antibody targeting PD-L1. These are investigational programs in this story; their inclusion here is not a treatment recommendation or a claim of U.S. approval. [2]
Market Position
Target Customers
EQRx sought relationships with payers, health systems, and providers who could adopt lower-priced medicines if approved. The patient benefit depended on clinical adoption, coverage, and how savings reached patients, not solely on a company's announced list price. [1]
Market Size
EQRx targeted categories with high drug spending, but the sources reviewed do not establish the obtainable market for its particular candidates. A large category alone cannot establish demand for a new medicine before clinical and regulatory review.
Competition
The company proposed competing with established branded medicines. Existing manufacturers had approved products, prescribing relationships, and negotiated coverage; EQRx needed sufficient evidence and a viable commercial path for each alternative. Its own filing warned that the planned pricing model was untested. [1]
Business Model
EQRx intended to develop a catalog and sell approved drugs through relationships with health plans and systems. It expected lower, more transparent prices to encourage adoption. In its 2021 filing, the company explicitly stated that it did not have approved products and that its pricing model might not succeed. The reviewed evidence does not establish commercial product revenue from the proposed model. [1]
Traction
EQRx secured substantial financing and listed publicly. Those events funded the plan but did not establish that its medicines could be approved, priced, and adopted as proposed. Its 2021 report described payer and health-system relationships as part of the planned buyers club; the sources here do not establish actual purchases of an approved EQRx drug. [8] [1]
Outcome and evolution
Clinical evidence changed the economics
Fierce Biotech's review of the merger filing reported that the FDA wanted another phase 3 study for sugemalimab in a representative U.S. population against an approved therapy. EQRx later said it lacked a commercially viable U.S. path for that candidate in the indication discussed. A further trial would add time and cost to a model that depended on bringing competing products to market efficiently. The reporting does not show that the price strategy alone caused the outcome. [2]
A merger filing says later clinical data also reduced the expected market opportunity for lerociclib. EQRx reprioritized its portfolio, discontinued certain studies, and significantly reduced its organization. These were changes to a particular pipeline and plan; they do not prove that every lower-price drug strategy would fail. [9]
The buyer acquired cash and ended the pipeline
Revolution Medicines closed the acquisition on November 9, 2023. It expected approximately $1.1 billion in net cash after estimated wind-down and transition costs, and said all EQRx programs were being wound down. The acquisition funded Revolution's own oncology development; it did not continue EQRx's original portfolio as a lower-price product catalog. [3]
Key Lessons
- Price depends on approval. EQRx's discount plan could not reach buyers until its medicines cleared the evidence and regulatory steps for their intended markets. [2]
- Separate funding from product validation. EQRx raised large rounds and listed publicly, while its filing said the proposed commercial model remained untested. [1]
- Read the terms of an exit. Revolution's deal primarily added capital for its own programs and wound down EQRx's portfolio. The acquisition did not establish a market for the original catalog. [3]